Dianthus TherapeuticsDNTH
About: Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
Employees: 78
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
67% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 24
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
11.78% more ownership
Funds ownership: 106.9% [Q3] → 118.68% (+11.78%) [Q4]
4% more funds holding
Funds holding: 91 [Q3] → 95 (+4) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 5 [Q3] → 5 (+0) [Q4]
11% less capital invested
Capital invested by funds: $859M [Q3] → $766M (-$93.2M) [Q4]
31% less call options, than puts
Call options by funds: $9K | Put options by funds: $13K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Wedbush Laura Chico 19% 1-year accuracy 10 / 54 met price target | 102%upside $36 | Outperform Reiterated | 12 Mar 2025 |
Guggenheim Yatin Suneja 24% 1-year accuracy 8 / 34 met price target | 370%upside $84 | Buy Reiterated | 12 Mar 2025 |
HC Wainwright & Co. Swayampakula Ramakanth 18% 1-year accuracy 36 / 202 met price target | 124%upside $40 | Buy Reiterated | 12 Mar 2025 |
Financial journalist opinion
Based on 3 articles about DNTH published over the past 30 days









